Abstract
Monoamine oxidase B inhibitors are of particular importance in the treatment of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Herein described is pharmacophore generation and atom-based 3D-QSAR analysis of previously reported furan based MAO-B inhibitors in order to get insight into their structural requirements responsible for high affinity. The best pharmacophore model generated with the five-point hypotheses of ADHRR: hydrogen bond acceptor (A), hydrogen bond donor (D), hydrophobic (H) and two aromatic rings (R1 & R2). On the basis of generated model, a statistically valid 3D-QSAR with good predictability was developed. Molecular docking of lead compound showed binding energy of -8.66 kcal/mol with a predicted inhibition constant of 0.448 μM towards MAO-B.
Keywords: MAO-B, 3D-QSAR, Phase, Pharmacophore, Furanochalcones.
Central Nervous System Agents in Medicinal Chemistry
Title:Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B
Volume: 16 Issue: 2
Author(s): Bijo Mathew, Sanal Dev, Jerad Suresh, Githa E. Mathew, Baskar Lakshmanan, Abitha Haridas, Fajeelath Fathima and Girish K. Krishnan
Affiliation:
Keywords: MAO-B, 3D-QSAR, Phase, Pharmacophore, Furanochalcones.
Abstract: Monoamine oxidase B inhibitors are of particular importance in the treatment of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Herein described is pharmacophore generation and atom-based 3D-QSAR analysis of previously reported furan based MAO-B inhibitors in order to get insight into their structural requirements responsible for high affinity. The best pharmacophore model generated with the five-point hypotheses of ADHRR: hydrogen bond acceptor (A), hydrogen bond donor (D), hydrophobic (H) and two aromatic rings (R1 & R2). On the basis of generated model, a statistically valid 3D-QSAR with good predictability was developed. Molecular docking of lead compound showed binding energy of -8.66 kcal/mol with a predicted inhibition constant of 0.448 μM towards MAO-B.
Export Options
About this article
Cite this article as:
Mathew Bijo, Dev Sanal, Suresh Jerad, E. Mathew Githa, Lakshmanan Baskar, Haridas Abitha, Fathima Fajeelath and K. Krishnan Girish, Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B, Central Nervous System Agents in Medicinal Chemistry 2016; 16 (2) . https://dx.doi.org/10.2174/1871524915666150319122540
DOI https://dx.doi.org/10.2174/1871524915666150319122540 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Weight Loss Following Roux-en-Y Gastric Bypass Surgery: A Systematic Review of Psychosocial Predictors
Current Psychiatry Reviews Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets Flunarizine Dihydrochloride Nanoemulsion for Migraine Nasal Drug Delivery: Fabrication, Characterization and In Vitro Study
Drug Delivery Letters Cell Adhesion Molecules in Gene and Cell Therapy Approaches for Nervous System Repair
Current Gene Therapy Correlation between Decreased Parasympathetic Activity and Reduced Cerebrovascular Reactivity in Patients with Lacunar Infarct
Current Neurovascular Research Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Once-a-Day (QD) vs Twice-Daily (BID) Nevirapine as Simplification in PITreated Patients After 2 mos. of BID Induction
Current HIV Research Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Ischemic Brain Injury
Recent Patents on CNS Drug Discovery (Discontinued) Antinociceptive Activities of Some 4,5-Dihydro-1H-Pyrazole Derivatives: Involvement of Central and Peripheral Pathways
Letters in Drug Design & Discovery Function and Expression Pattern of Nonsyndromic Deafness Genes
Current Molecular Medicine A Study on Leukemic and Non-small Cell Lung Cancer Efficacy of Novel Isoxazoles Synthesized by Microwave Irradiation
Letters in Drug Design & Discovery Oral Tolerance in the Treatment of Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Review of Evidence and Perspectives of Flavonoids on Metabolic Syndrome and Neurodegenerative Disease
Protein & Peptide Letters The Effect of Potato Almond Orange Cookies on their Weight, BMI, Hemoglobin, and Lymphocyte Status of Undernourished Older People during COVID-19 Pandemic
Current Nutrition & Food Science A Novel Approach to Refractory Epilepsy by Targeting Pgp Peripherally and Centrally: Therapeutic Targets and Future Perspectives
CNS & Neurological Disorders - Drug Targets Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Neurotoxicity of β-Amyloid Protein: Oligomerization, Channel Formation and Calcium Dyshomeostasis
Current Pharmaceutical Design Epigenetic Regulation of Memory-Therapeutic Potential for Disorders
Current Neuropharmacology Bipolar Spectrum Disorder: Origins and State of the Art
Current Psychiatry Reviews